EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Impact of alternating electric fields therapy for newly diagnosed WHO grade 4 astrocytoma on patient survival: a real-world propensity-score adjusted prospective multicenter study

Peter Y M Woo, Jenny K S Pu, Lai-Fung Li, Desiree K K Wong, Victor K H Hui, Danny T M Chan, Michael W Y Lee, Tony K T Chan, Jason M K Ho, Ka-Man Cheung, Teresa P K Tse, Sarah S N Lau und 7 weitere

Journal of Neuro-Oncology · 2025

DOI: 10.1007/s11060-025-04985-3 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Neuro-Oncology, 2025. Verfasst von Peter Y M Woo und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Prince of Wales Hospital, 30-32 Ngan Shing Street, Shatin, N.T, Hong Kong. wym307@ha.org.hk. Hauptthemen laut MEDLINE: Brain Neoplasms, Astrocytoma, Electric Stimulation Therapy. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Alternating electric fields (AEF) therapy in addition to temozolomide chemoradiotherapy (TMZ CRT) is increasingly being recommended as first-line treatment for patients with newly-diagnosed WHO grade 4 astrocytoma. However, few have validated this treatment with real-world evidence.

Methods

Consecutive adult patients with newly-diagnosed WHO grade 4 astrocytoma treated with adjuvant TMZ CRT across all neuro-oncology centers in Hong Kong were reviewed. Identified from a territory-wide prospective glioma registry, propensity-score matching (1:2) was performed to match patients that either received TMZ CRT with AEF or TMZ CRT alone. Matching was according to age, Karnofsky performance status, IDH-1 mutation, p MGMT methylation and extent of resection. The primary endpoint was overall survival (OS). Secondary endpoints were the incidence of AEF-associated adverse effects and mean monthly treatment compliance.

Results

141 patients were reviewed, of whom 47 patients received AEF with TMZ CRT and 94 had CRT alone. Multivariate Cox proportional hazards analysis revealed that patients with p MGMT- methylated tumors (mOS: 30.8 months vs. 16.7 months [95% CI: 1.9–4.7] and those that received AEF (mOS: 22.8 vs. 14.3 months [95% CI: 1.9–4.7]) had longer OS. AEF therapy patients had a mOS benefit of 8.5 months. The mean monthly treatment compliance was 74 ± 12%. A compliance threshold of 60% conferred a survival benefit of 4.1 months (mOS: 21.5 months vs. 17.4 months [95% CI: 0.10–0.96]). The only identified AEF-associated adverse reaction was scalp dermatitis that occured in 77% (36/47) of patients.

Conclusion

This post-approval study offers real-world evidence in support of the use of AEF therapy as first-line treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Brain NeoplasmsAstrocytomaElectric Stimulation TherapyHumansMaleFemaleMiddle AgedAdultProspective StudiesTemozolomidePropensity ScoreAgedAntineoplastic Agents, AlkylatingYoung AdultFollow-Up StudiesNeoplasm GradingCombined Modality Therapy

Stichwörter der Autor:innen

Alternating electric fieldsGlioblastomaOverall survivalTemozolomide chemoradiotherapyTumor treating fieldsWHO grade 4 astrocytoma

Substanzen

TemozolomideAntineoplastic Agents, Alkylating

Autor:innen und Institutionen

  • Department of Neurosurgery, Prince of Wales Hospital, 30-32 Ngan Shing Street, Shatin, N.T, Hong Kong. wym307@ha.org.hk.
  • Department of Neurosurgery, Queen Mary Hospital, Hong Kong Island, Hong Kong.
  • Department of Neurosurgery, Prince of Wales Hospital, 30-32 Ngan Shing Street, Shatin, N.T, Hong Kong.
  • Department of Neurosurgery, Pamela Youde Nethersole Eastern Hospital, Chai Wan, Hong Kong.
  • Department of Neurosurgery, Princess Margaret Hospital, Kwai Chung, Hong Kong.
  • Department of Neurosurgery, Tuen Mun Hospital, Tuen Mun, Hong Kong.

Zitieren

APA

Woo, P. Y. M., Pu, J. K. S., Li, L. F., Wong, D. K. K., Hui, V. K. H., Chan, D. T. M., Lee, M. W. Y., Chan, T. K. T., Ho, J. M. K., Cheung, K. M., Tse, T. P. K., Lau, S. S. N., Chow, J. S. W., Ko, N. M. W., Loong, H. H. F., El-Helali, A., Lam, T. C., Cheung, F. C., & Poon, W. S. (2025). Impact of alternating electric fields therapy for newly diagnosed WHO grade 4 astrocytoma on patient survival: a real-world propensity-score adjusted prospective multicenter study. Journal of Neuro-Oncology. https://doi.org/10.1007/s11060-025-04985-3

Vancouver

Woo PYM, Pu JKS, Li LF, Wong DKK, Hui VKH, Chan DTM, et al. Impact of alternating electric fields therapy for newly diagnosed WHO grade 4 astrocytoma on patient survival: a real-world propensity-score adjusted prospective multicenter study. Journal of Neuro-Oncology. 2025. doi:10.1007/s11060-025-04985-3

BibTeX
@article{Woo2025,
  author = {Woo, Peter Y M and Pu, Jenny K S and Li, Lai-Fung and Wong, Desiree K K and Hui, Victor K H and Chan, Danny T M and Lee, Michael W Y and Chan, Tony K T and Ho, Jason M K and Cheung, Ka-Man and Tse, Teresa P K and Lau, Sarah S N and Chow, Joyce S W and Ko, Natalie M W and Loong, Herbert H F and El-Helali, Aya and Lam, Tai-Chung and Cheung, Fung-Ching and Poon, Wai-Sang},
  title = {Impact of alternating electric fields therapy for newly diagnosed WHO grade 4 astrocytoma on patient survival: a real-world propensity-score adjusted prospective multicenter study},
  journal = {Journal of Neuro-Oncology},
  year = {2025},
  doi = {10.1007/s11060-025-04985-3}
}
Kostenlos starten →